Helix BioPharma Corp. (HBPCF)

Helix BioPharma Balance Sheet

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Cash & Equivalents	0.07	1.08	0.81	3.25	3.57
Cash & Short-Term Investments	0.07	1.08	0.81	3.25	3.57
Cash Growth	-93.99%	33.79%	-75.15%	-8.78%	-15.82%
Other Receivables	0.12	0.05	0.06	0.28	0.35
Receivables	0.12	0.05	0.06	0.28	0.35
Prepaid Expenses	0.22	0.32	0.13	0.16	0.1
Total Current Assets	0.41	1.46	1	3.7	4.02
Property, Plant & Equipment	0	0.03	0.03	0.04	0.05
Other Intangible Assets	18.39	0	-	-	-
Total Assets	18.8	1.49	1.03	3.73	4.07
Accounts Payable	2.3	0.86	0.49	0.6	1.47
Accrued Expenses	0.58	0.72	0.38	0.35	0.38
Short-Term Debt	0.34	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	2.47	2.03
Other Current Liabilities	-	-	1	-0	-
Total Current Liabilities	3.22	1.58	1.87	3.41	3.87
Long-Term Debt	-	-	-	-	1.58
Other Long-Term Liabilities	-	-	-	0	-
Total Liabilities	3.22	1.58	1.87	3.41	5.46
Common Stock	179.29	158.57	152.07	147.51	139.66
Additional Paid-In Capital	48.3	47.36	44.14	37.59	27.87
Retained Earnings	-215.88	-210.67	-201.41	-195.12	-188.55
Comprehensive Income & Other	3.87	4.65	4.36	10.34	19.63
Total Common Equity	15.59	-0.09	-0.85	0.32	-1.39
Shareholders' Equity	15.59	-0.09	-0.85	0.32	-1.39
Total Liabilities & Equity	18.8	1.49	1.03	3.73	4.07
Total Debt	0.34	-	-	2.47	3.61
Net Cash (Debt)	-0.27	1.08	0.81	0.78	-0.05
Net Cash Growth	-	33.79%	3.06%	-	-
Net Cash Per Share	-0.00	0.02	0.02	0.03	-0.00
Filing Date Shares Outstanding	76.38	49.02	43.33	34.86	28.49
Total Common Shares Outstanding	74.16	49.02	40	34.36	28.23
Working Capital	-2.81	-0.12	-0.88	0.28	0.14
Book Value Per Share	0.21	-0.00	-0.02	0.01	-0.05
Tangible Book Value	-2.8	-0.09	-0.85	0.32	-1.39
Tangible Book Value Per Share	-0.04	-0.00	-0.02	0.01	-0.05
Machinery	1.22	1.46	1.44	1.44	1.43
Leasehold Improvements	-	0.36	0.36	0.36	0.36

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.